The Request for Information (RFI) on the federal regulation of cannabidiol, popularly known as CBD, was published on Thursday by a bipartisan and bicameral group of US senators.
The group consists of Cathy McMorris Rodgers (R-Wash.) of the House Energy and Commerce Committee, Bernie Sanders (I-VT) of the Senate Health, Education, Labor and Pensions Committee, and Bill Cassidy (R-LA) of the ranking committee.
An RFI is a research instrument that seeks information from professionals in relevant fields, research bodies, and organizations about the capabilities, best practices, laws, and regulations of a certain service or agency.
The group requests information from stakeholders and subject matter experts, including a description of the current CBD product market and an explanation of how the lack of federal regulation of CBD led to the emergence of a market for intoxicating, synthetically produced substances.
The FDA [Food and Drug Administration] said in January 2023 that it would like to collaborate with Congress to develop a legislative strategy for the regulation of CBD products, according to the request.
Consumer Safety and Stability in US CBD Market
We are evaluating the viability of a regulatory framework for CBD products produced from hemp that emphasizes consumer safety and offers stability to the US market.
We want written responses to the following questions and look forward to collaborating with interested parties on this process.
The letter also emphasized the fact that hemp was excluded from the Controlled Substances Act’s definition of marijuana in the Agriculture Improvement Act of 2018, often known as the 2018 farm bill.
The term was also broadened in the bill to refer to all parts of the cannabis sativa L. plant, including the seeds, and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether or not they are growing.
They must also have a concentration of delta-9 tetrahydrocannabinol of no more than 0.3 percent on a dry weight basis.